Inhibikase Therapeutics Inc. (IKT) News

Inhibikase Therapeutics Inc. (IKT): $2.64

0.11 (+4.35%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add IKT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#261 of 357

in industry

Filter IKT News Items

IKT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IKT News Highlights

  • For IKT, its 30 day story count is now at 2.
  • Over the past 15 days, the trend for IKT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about IKT are DEC, MG and PD.

Latest IKT News From Around the Web

Below are the latest news stories about INHIBIKASE THERAPEUTICS INC that investors may wish to consider to help them evaluate IKT as an investment opportunity.

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders. Dear Fellow Shareholders of Inhibikase Therapeutics: What a ride it has been in 2023. The year began with a quick r

Yahoo | December 19, 2023

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications - - Bioequivalence to 400 mg and 600 mg imatinib mesylate completed with minimal adverse events - BOSTON and ATLANTA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, P

Yahoo | December 4, 2023

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ETBOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the third quarter ended September 30,

Yahoo | November 14, 2023

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" rather than "third quarter." BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's

Yahoo | November 7, 2023

Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023

BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the third quarter ended September 30, 2023, on Tuesday, November 14, 2023, after the close of U.S.

Yahoo | November 7, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today highlighted an analysis of eleven unblinded participants from the 201 Trial evaluating risvodetinib (IkT-148009) in untreated Parkinson’s disease. T

Yahoo | October 16, 2023

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment o

Yahoo | October 4, 2023

Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity

BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders in response to recent price volatility. Dear Fellow Shareholders of Inhibikase Therapeutics: We have watched, as ha

Yahoo | September 20, 2023

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has developed a novel tablet formulation of IkT-148009, designed to improve drug exposure and overcome existing challenges related to patient use.

Yahoo | August 24, 2023

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will deliver two oral presentations at the International Congress of Parkinson's Disease and Movement Disorders. Th

Yahoo | August 22, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!